Analysts Offer Predictions for SCYNEXIS FY2029 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Analysts at Brookline Capital Management decreased their FY2029 earnings per share estimates for SCYNEXIS in a research report issued on Monday, August 18th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of $0.38 for the year, down from their prior forecast of $0.39.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09. The business had revenue of $1.36 million during the quarter, compared to analyst estimates of $0.15 million. SCYNEXIS had a negative return on equity of 43.04% and a negative net margin of 599.05%.

Separately, Wall Street Zen initiated coverage on SCYNEXIS in a research report on Friday, May 16th. They issued a “sell” rating for the company.

SCYNEXIS Trading Up 3.8%

NASDAQ SCYX opened at $0.82 on Wednesday. The firm has a market capitalization of $34.37 million, a P/E ratio of -2.05 and a beta of 1.64. The business has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $0.89. SCYNEXIS has a 12 month low of $0.66 and a 12 month high of $1.79.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC bought a new position in SCYNEXIS in the 4th quarter valued at $25,000. Jane Street Group LLC bought a new position in SCYNEXIS in the 2nd quarter valued at $27,000. Millennium Management LLC bought a new position in SCYNEXIS in the 4th quarter valued at $31,000. JPMorgan Chase & Co. bought a new position in SCYNEXIS in the 4th quarter valued at $49,000. Finally, Squarepoint Ops LLC bought a new position in SCYNEXIS in the 4th quarter valued at $53,000. Institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.